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Abstract
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Pennsylvania has the third highest rate of death due to drug overdose (44.3 per 100,000) in the
country, which is significantly higher than the national rate. This continues to have drastic societal
impact. Medication assisted treatment (MAT), which includes opioid agonist medications, is the
gold standard in treatment for OUD; however, a significant gap remains between the number of
individuals in need of treatment and the number of MAT providers. Penn State Health established
a system to address the opioid epidemic through the Pennsylvania Coordinated Medication
Assisted Treatment program utilizing lessons learned from existing validated models. Connecting
primary care sites and hospital systems through a combination of Hub and Spoke, bridge clinic
services provided at the Hub, peer recovery services, Project Extension for Community Health
Outcomes (ECHO), and layered emergency department (ED) initiation of buprenorphine, this
model is an innovative approach that addresses many known barriers to MAT treatment initiation.
Early results within the first six months indicate significantly shortened wait time for patients
seeking treatment, provision of waiver training to 70 local physicians to prescribe buprenorphine,
and improved knowledge and ability to provide patient care for providers participating in our first
Project ECHO cohort.
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1.

Introduction
Opioid use disorder (OUD) is one of the largest health crises of this generation. With drug
overdose deaths increasing to over 70,000 in 2017 (Drug Overdose Death Data) and those
resulting from opioid misuse at over 47,000 (Drug Overdose Death Data), the United States
(US) has surpassed the number of deaths experienced at the peak of the HIV/AIDS epidemic
in the 1990s (Case & Deaton, 2015). In 2017, Pennsylvania had the third highest rate of
death due to drug—primarily but not exclusively opioid—overdose (44.3 per 100,000) in the
country, which was significantly higher than the national rate (21.7 per 100,000, (Centers for
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Disease Control, 2019). Through the Pennsylvania Coordinated Medication Assisted
Treatment (PacMAT) program, Centers of Excellence, and the expansion of Medicaid in
Pennsylvania (72,675 OUD patients covered in 2017), treatment for OUD patients became
more accessible. Medication assisted treatment (MAT), which includes opioid agonist and
partial agonist medications such as methadone and buprenorphine respectively, is the gold
standard in evidence-based treatment for OUD with survival and treatment retention rates up
to seven times that of drug-free modalities (Connery, 2015). Despite having effective
treatment, a significant gap exists between the number of individuals in need of treatment,
approximately 2.5 million (Substance Abuse and Mental Health Administration, 2014), and
the number actually receiving treatment. This disparity exists, at least in part, because of the
relatively small number of MAT providers, approximately 68,000 (Substance Abuse and
Mental Health Association, 2019). Certainly, increasing the number of providers would be a
key element of any effective intervention, but it is not enough to have more providers; the
providers must be where they are needed. The overdose death rates in rural counties is
approaching those in urban settings, increasing the urgency to have MAT providers in rural
communities. As of June 2018, the number of buprenorphine treatment providers (n = 24)
within a 25-mile radius of the city of Harrisburg was the same (n = 24) within a 50-mile
radius, demonstrating the geographic disparity in access to treatment (Substance Abuse and
Mental Health Association, 2019).

Author Manuscript

While geography is a serious and common barrier to increasing access to care, it is not the
only one. To be authorized to prescribe buprenorphine, the most commonly used medication
for outpatient treatment of OUD, physicians must obtain a waiver under the Drug Addiction
Treatment Act (DATA). Currently, about 5% of practicing US physicians are DATAwaivered, and most waivered providers do not prescribe to their maximum waiver capacity
(Huhn & Dunn, 2017). Lack of confidence in providing MAT among physicians further
compounds the problem (Bart, 2012), and is reinforced by limited access to addiction
experts for consultation and referral if necessary. Other reasons include the lack of multiple
providers within one clinic to prescribe buprenorphine, the lack of mental health and other
psychosocial support within the clinic, and lack of institutional support (Hutchinson, Catlin,
Andrilla, Baldwin, & Rosenblatt, 2014). Moreover, stigma against those with OUD remains
prevalent among prescribers and among those struggling with OUD (Can & Tanrıverdi,
2015). Therefore, critical next steps to combatting the overdose epidemic include both
increasing the number of providers who are DATA-waived and increasing provider
confidence to provide MAT at full capacity.

Author Manuscript

Any system to intervene in the overdose epidemic must first understand and build on
effective system-based models of MAT delivery. Vermont’s Hub and Spoke system is an
example of capacity expansion in which a Hub (i.e., a specialty clinic with addiction
medicine specialists) is connected with spoke clinics that provide frontline care and referral
for patients with OUD. Vermont’s system, initiated in 2012, led to a 64% increase in DATAwaived physicians as well as a 50% increase in patients served per physician waivered
(Brooklyn & Sigmon, 2017). With its origin at the University of New Mexico, Project
ECHO (Extension for Community Healthcare Outcomes) is a collaborative model of
medical education and care management, increasing access to treatment in rural and
underserved areas by engaging specialist teams with primary care providers in virtual caseJ Subst Abuse Treat. Author manuscript; available in PMC 2020 May 01.
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based discussion and brief lectures that has been readily deployed to expand MAT access.
Project ECHO began addressing OUD in 2005 and increased the number of DATA-waived
providers, elevating New Mexico’s status to fourth ranked state for DATA-waived physicians
per capita (Komaromy et al., 2016; Komaromy, Bartlett, Manis, & Arora, 2017).
Replications of this model have demonstrated improved provider self-efficacy and
confidence in managing patients who are prescribed MAT (Dubin et al., 2015).
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Increasing MAT capacity by expanding the number of waivered physicians and improving
their confidence to treat addresses only one of the obstacles to overcoming the overdose
epidemic. Logistical challenges connecting a patient to care rapidly must be solved: once a
patient is identified, that patient must be referred to and started on treatment quickly to
reduce the risk of overdose while awaiting care. In Massachusetts, the Massachusetts
General Hospital’s bridge clinic has helped patients obtain buprenorphine quickly, leading to
significant increases in treatment retention at 30 days (Hostetter & Klein, 2017). At the Yale
emergency department, DATA-waived emergency medicine physicians facilitated a warm
hand-off twice as successfully as matched controls who did not receive buprenorphine in the
emergency room (D’Onofrio et al., 2015).
A public health challenge as serious at the overdose epidemic demands all demonstrated
effective interventions be used simultaneously. This paper describes a systems approach to
addressing MAT expansion and treatment initiation in Central Pennsylvania, a unique hybrid
of Hub and Spoke, bridge clinic and emergency department (ED)-initiated buprenorphine.
An OUD focused Project ECHO further supports the spoke providers to overcome
inadequate MAT knowledge and experience, poor access to resources and support, and a
negative perception of treating OUD patients.
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2.

Methods

Author Manuscript

Penn State established a system in 2017 (Fig. 1) to address the overdose epidemic, supported
by the Pennsylvania Department of Health-funded PacMAT Program. Our mission was to
provide and expand comprehensive, patient-centered and innovative evidence-based
treatment to individuals with substance use disorder in south central Pennsylvania. Using
existing validated models, this initiative connected primary care sites and hospital systems
through a combination of Hub and spoke, bridge clinic services provided at the Hub, peer
recovery services, and layered emergency department (ED) initiation of buprenorphine.
Treatment retention was an important variable of interest, and the model was designed to
maximize retention so that an impact could be made on the overdose death rates in the
region. A year after the Penn State system started treating substance use disorder, it
expanded its ability to reach rural communities of Pennsylvania through addition of Project
ECHO to provide clinical support to our spokes and other providers across the region. The
Hub and Spoke element of the system ameliorated the isolation of specialty addiction
treatment from other medical and psychiatric services. The system’s bridge clinic services
decreased patient wait time, allowed immediate engagement in treatment and decreased risk
of treatment drop out while awaiting an appointment at the preferred treatment setting. As
Project ECHO sessions wove together providers of care, peer recovery services removed
barriers separating one level of care from another, and allowed patients to move efficiently
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among settings as appropriate and also access peer-led support groups. Further, the program
partnered with Emergency Departments as first points of contact for many people suffering
from OUD and established Emergency Department initiation of buprenorphine as a route to
rapid MAT access. We describe components of this program below.
2.1.

Catchment demographics

Author Manuscript

Paralleling the national trend, Pennsylvania’s high rates of drug overdose deaths were not
restricted to urban areas, as rates of drug-related overdose deaths in rural counties
approached those of urban settings. At the time treatment for substance use disorder
launched at Penn State Health, the health system drew from a population in six south central
Pennsylvanian counties, five of which are rural: Cumberland, Dauphin, Franklin, Lancaster,
Lebanon, and York (Fig. 2). In the catchment area, rates of overdose deaths ranged from 21
to 39 per 100,000 residents. Although the catchment area focused in the six counties
described above, the patients served came from as many as ten surrounding counties.
2.2.

Protection of human subjects
The Human Subjects Protection Office at the Penn State College of Medicine determined the
activities described did not require formal IRB review because the research met the criteria
for exempt research according to the policies of the institution and provisions of applicable
federal regulations.

2.3.

Hub

Author Manuscript
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The system Hub—located in the city of Harrisburg, Dauphin County—was licensed as an
opioid treatment program (OTP) located within a psychiatric hospital. The OTP opened
providing all forms of MAT (methadone, daily dosed buprenorphine-naloxone, prescribed
buprenorphine-naloxone and extended-release naltrexone) in combination with
comprehensive OUD psychosocial services. Two part-time physicians and a full-time
certified nurse practitioner practiced on site, as well as several residents and fellow
physicians from Penn State Health rotating through the site for teaching and patient care.
Nine counselors practiced on site at a patient-counselor ratio of 35:1 to provide individual
counseling and outpatient level services. In addition, the Hub linked with psychiatric
services within the hospital, including inpatient treatment and partial hospitalization. A fulltime certified recovery specialist worked with patients on vocational rehabilitation to assist
patients who are ready to reenter the workforce. Additionally, the clinic used contingency
management—an evidence-based behavioral intervention based on applied behavior analysis
—as an incentive to keep patients participating at their recommended level of care (Petry,
Alessi, Olmstead, Rash, & Zajac, 2017). Patient rewards total—at most—$50 per patient per
year were budgeted in-kind.
The Hub provided daily, directly-observed therapy for patients, serving as an intensive
outpatient clinic in support of 12 surrounding primary care, emergency department and
primary psychiatric spoke sites. The Hub’s engagement with spoke sites primarily existed as
a higher level of support with daily medication treatment and on-site counseling with the
goal of returning patients to spoke sites once stabilized. Examples of Hub patients included
pregnant women and patients requiring “urgent care” or “bridge appointments” in need of
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medication initiation within 24–48 h after identification prior to their first appointment at a
spoke site. To improve the ability of the Hub to reach new patients, its affiliated emergency
department was rendered capable of initiating buprenorphine on site and transferring
patients to the Hub for treatment intake within 24–48 h. Finally, the Hub fostered strong
relationships with a county jail, drug court and the local county drug and alcohol authority.
Patients engaged in work-release or going through diversion courts, as well as those who
need county funds for MAT, received services at this clinic.
2.4.

Clinic spokes

Author Manuscript

The spoke clinics included 18 buprenorphine waivered physicians across 12 spoke sites from
Penn State Medical Group practices, the Milton S. Hershey Medical Center Emergency
Department, several federally qualified health centers, and primary care sites accepting
Medicaid patients and psychiatric practices. Spoke sites accessed enhanced care
management to help patients navigate from spoke to Hub and Hub to spoke, providing
higher levels of care when needed. A phone call by the patient or provider to the care
manager led to a hand-off that facilitated patients’ transition to Hub for medication
stabilization, either with daily methadone or buprenorphine. This allowed for greater
treatment retention for unstable patients. On those occasions when a patient at a spoke site
wished to initiate care, but no appointment was available at the spoke—see Table 1— the
spoke site could access the system’s urgent care or “bridge” services at the Hub, allowing
patients to begin treatment rapidly and return to the spoke at the next available appointment
for MAT. Bridge services reduced barriers and prevented patients from being lost to care.
Potential patient visit wait times varied depending on the number of full-day clinics
available per month, per spoke prior to our clinic opening (see Table 1). This system of care
supported physicians with utilizing administrative time, completing paperwork needed for
insurance companies or disability applications, and following up with any other question or
patient need.
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2.5.

Peer recovery specialist services

Author Manuscript

Peer-based recovery support services using peer recovery specialists, also referred to as care
managers or care management support, facilitated hand-offs between spoke and Hub in this
system. These specialists, who were in long-term recovery themselves, ensured that patients
adhered to medical and behavioral health appointments while navigating them through care
transitions. Each spoke site had a corresponding peer recovery specialist supported by
Medicaid behavioral health reimbursement and grants, through a non-profit organization
called the Recovery, Advocacy, Service and Empowerment (RASE) project. Peer recovery
specialists assisted patient transitions to different care settings by providing transportation,
help with scheduling appointments, and support at appointments. Their consistent
involvement in a patient’s care reduced stigma and a patient’s feeling of being dismissed by
spoke sites. Peer support specialists also coordinated location-appropriate and convenient
MAT access based on individual patient needs, insurance enrollment navigation, and
established connections with peer-led community support networks, including sober support
networks.
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All providers at Milton S. Hershey Medical Center Emergency Department (ED) received
training to become buprenorphine waivered and prescribed buprenorphine to patients seen
after overdose or in withdrawal since April 2018. As such, the affiliated ED became one of
very few in Pennsylvania with a completely buprenorphine waivered provider staff. ED
integration was only possible by combining a physician champion, support from senior
leadership, and a protocol designed to ensure our ED providers did not feel they were
practicing outside of their scope of practice. Importantly, our OTP clinic served as a reliable
aftercare resource following treatment initiation. We also established procedures to minimize
multiple ED visits within a 30 day period for patients, so that our ED providers would
prescribe a maximum of 2 days of medication per patient. Once a patient with substance use
disorder was identified, ED social workers called the 24-hour admissions line to make an
appointment at the Hub within 1–2 days.

Author Manuscript

2.7.

Project ECHO
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Project ECHO is a model with the power to rapidly transfer knowledge and exponentially
increase capacity to deliver best-practice care to underserved populations (Arora et al.,
2014). The ECHO model has four core principles: (1) use technology to leverage scarce
resources; (2) share best practices to reduce disparities; (3) employ case-based learning to
master complexity; (4) monitor outcomes to ensure benefit. ECHO sessions use
videoconferencing technology as a platform for telementoring and collaborative care, with a
Hub and Spoke structure (Fig. 3). The ECHO model is not “telemedicine” where specialists
assume the care of the patient; it is a guided practice model aimed at practice improvement,
in which the PCP retains responsibility for managing the patient, operating with increasing
independence as skills, confidence, and self-efficacy grow (Komaromy et al., 2016). The
ECHO model evaluates outcomes within Moore’s Levels for CME framework (Davis,
Barnes, & Fox, 2003). At the provider level, these outcomes include participation,
satisfaction, learning, competence, and performance.
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Project ECHO launched at Penn State in November 2018 to address OUD within the
PacMAT model. In the first cohort, twenty newly DATA-waivered providers enrolled to
participate in twelve, one-hour sessions given every other week. Community-based
providers (the spokes) participated in weekly teleECHO clinics with a multi-disciplinary
specialty team at Penn State that included Addiction Medicine specialists, a pharmacist, a
peer recovery specialist, social workers, and guest experts including an obstetrician,
hepatologist, psychologist and psychiatrist. Weekly teleECHO sessions featured
presentations of deidentified patient cases by primary care providers and team members. The
ECHO specialist and primary care teams collaborated to discuss the case and develop
recommendations for patient care. Following the case discussion, a brief lecture was given
by one of the specialists. After each session, participants received a short survey asking
questions about whether or not that particular session resulted in increased knowledge,
decreased professional isolation, an improved ability provide appropriate care to patients,
satisfaction with the information provided, and relevance to their practice.
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Results
The Hub introduced different system components at different times, beginning in November
2017 with the introduction of Hub and Spoke clinics and bridge visits. ED initiation of
buprenorphine commenced in April 2018 with 30 newly waivered physicians. Project ECHO
sessions began in November 2018. Results reported reflect the first six months of clinic
operation, including Hub and Spoke, bridge clinic, and one month of ED buprenorphine
initiation.

3.1.

Preliminary treatment patterns

Author Manuscript

Within the first 6 months of the Hub opening, 222 intakes were scheduled and 180 patients
were seen, with a retention-to-intake rate of 81%. There were no recorded reasons for the 42
patients who did not appear for intake. Of the 180 patients, 62%, 37%, and 1% identified as
male, female, and transgender, respectively (Table 2). The average age of this patient
population was 36.3 years, with the majority identifying as Caucasian or white (82%). Of
the 180 patients, 127 began buprenorphine treatment, 9 began extended-release naltrexone
treatment, and 30 began methadone treatment. 14 patients declined any form of MAT. Of the
14, 3 were referred to an outside treatment center, 9 declined any MAT and 2 desired
counseling only. When stratifying the population by MAT type, the distribution of
methadone, buprenorphine and extended-release naltrexone were proportionate between
male and female clients.
3.2.

Current treatment pattern
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As of April 2019, the Hub treated over 600 individuals with 352 in active treatment. In
addition, 12 spoke sites treated 306 active patients. The spoke sites consisted of six primary
care clinics, one psychiatric clinic, one pain clinic, two EDs and two probation/parole and
county drug courts (Table 3). Ninety-two patients visited the Hub for a bridge appointment
(seen within 24 h) only, subsequently followed up at a spoke site, and 36 patients continued
treatment with the Hub after being initiated from the ED. Treatment retention rate was
defined as appointments kept within thirty days of data capture. During the first six months
of the hub program 43% of buprenorphine patients, 11% of extended-release naltrexone
patients, and 63% of methadone patients were retained in treatment. Future analyses will
determine treatment retention rates of each type of MAT for our total patient count at the end
of the grant period in September 2019.
3.3.

Project ECHO

Author Manuscript

The first Penn State ECHO OUD cohort included twenty primary care providers from
several specialties, including general internal medicine, family medicine and emergency
medicine. Together, these participants treated a combined 373 OUD patients in their
practices. The majority of ECHO participants (70%) provided care at our spoke clinics, but
we did include several participants from outside our hub-and-spoke system. Through Project
ECHO, we reviewed nine patient cases and provided 105 h of CME with positive provider
feedback. Results included increased knowledge of evidence-based OUD management (n =
109/121, 90%), decreased sense of professional isolation (n = 101/121, 83%), and selfreported improvement in ability to provide MAT to OUD patients (n = 107/121, 88%). In
J Subst Abuse Treat. Author manuscript; available in PMC 2020 May 01.
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addition, the Project ECHO platform, Zoom, provided virtual DATA-waiver training to 41
physicians in the state.

4.

Discussion

Author Manuscript

Penn State implemented a system of care in which patients received timely treatment close
to home and physicians felt supported and confident to treat opioid use disorder. Building
from validated models for MAT treatment and capacity expansion, Penn State has launched
an innovative system of care for OUD patients in central Pennsylvania that has the potential
to address many known barriers to MAT treatment initiation. Offering all forms of approved
MAT for OUD combined with advanced case management and treatment support services
has allowed our program to begin to fill the gap between those who need treatment for OUD
and those who actually receive it. We have begun to address the need for expanded MAT
offering in the primary care and emergency medicine settings by supporting 70 local
physicians to receive buprenorphine waiver training during our first year, including all of the
ED physicians at Penn State to facilitate acute treatment protocols. For those newly waivered
physicians, our OUD Project ECHO provides ongoing peer and expert support and
education.

Author Manuscript

Our initial retention rates from the first six months of the Hub opening are consistent with
other retention averages (Hser et al., 2014; Larochelle et al., 2018). We attribute these
unremarkable results to several factors. First, we implemented a unique model of care as a
new program. The launch of any clinical intervention demands careful navigation of state
and federal regulations and de novo development of processes, procedures, and practice
improvement. Establishing both our hub treatment programs and our coordination with the
peer recovery specialist network out of the hub required six months’ effort, equivalent to the
time of the data collection. Moreover, the launch of our Hub, hub-and-spoke and ED
services were staggered, and not all were available at the time of data collection. We are
hopeful that future data reviews will find a significant increase in our retention rates.
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There are many reasons for the rise of the overdose epidemic, which has developed over
time. Accordingly, addressing it will take a complex, multi-modal approach involving
prevention as well as treatment. A recent review of 12 successful primary care based MAT
models (Korthuis et al., 2017) showed all contained some degree of four key components:
(1) pharmacological therapy; (2) psychosocial services; (3) integration of care; and (4)
education and outreach. The Penn State model discussed here incorporates all components,
with the core Hub and Spoke system aligned closely with the Vermont approach (Brooklyn
& Sigmon, 2017) that brings care to a large area of small cities interspersed amidst a widely
scattered rural population, similar to that in central Pennsylvania. The care continuum aspect
of Hub and Spoke is an important model for both patients and providers; patients can receive
access to medication in a primary care spoke site location convenient and familiar to them
and providers are able to transfer patients requiring a higher level of care to the hub. There is
a key difference between the Vermont and Pennsylvania model worth noting. Vermont’s
model supports nurse care managers at every level of patient engagement provided by state
funding (Brooklyn & Sigmon, 2017). Our model relies on peer care managers, a form of
peer-based support that is widely used across a variety of healthcare settings and work to
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support patients by providing transitioning services to the community, employment, housing,
education, and a connection to support networks (Gagne, Finch, Myrick, & Davis, 2018).
We intend to show the sustainability of our approach by collecting data to demonstrate saved
health care costs for patients through reduced ED visits and inpatient admissions through
involvement of peer care managers. Demonstration of cost-savings may facilitate Medicaid
and commercial payor assistance in supporting these valuable team members.
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As discussed above, peer recovery services augment our Hub and Spoke system. We have
partnered with two such specialists to work with patients within our system. Peer-based
recovery support services are not new to the treatment of substance use disorder, but
adapting these services to a hub and spoke system of care provides a specific structure and
innovative approach to help individuals stay in treatment. Emerging evidence shows
potential benefits in the use of peer-based support services across a variety of settings
including substance abuse treatment (Gagne et al., 2018; Portillo, Goldberg, & Taxman,
2017; Rowe et al., 2007). The addition of these services aims to reduce known barriers to
treatment such as transportation from rural areas, stigma, and confidentiality concerns.
Before augmenting our Hub and Spoke system with peer-based support services, intake
appointment wait times at spoke sites often exceeded two weeks, increasing the risk of lossto-follow up. With the addition of peer-based care coordination we have been able to
connect patient with intake appointments in 24–48 h. Future studies will be beneficial to see
if actual wait times have been significantly impacted.

Author Manuscript
Author Manuscript

Provider and workforce barriers add another layer of complexity to effectively addressing
the overdose epidemic. In addition to the low number of waivered providers, limited
provider confidence and lack of specialty back up for complex cases and support services
are the most common barriers to providing outpatient addiction treatment cited by
physicians in rural locations (Andrilla, Coulthard, & Larson, 2017). The ECHO model has
been used to address substance use disorders among rural and underserved populations in
New Mexico since 2005 (Arora et al., 2014). In recent years its use has expanded across
several states and institutions combating the overdose epidemic; however Penn State is the
first to launch an OUD ECHO in Pennsylvania. ECHO has been shown to help providers
overcome many of the barriers they face to implementing MAT. Providers in a substance use
disorder-focused ECHO program reported that participation altered their care plan 77% of
the time, a result duplicated in our model, and they rated the value of the clinical input they
received as 4.8 out of 5 (Komaromy et al., 2017). A recent Agency for Healthcare Research
and Quality technical brief on MAT models of care for OUD in primary care commended
the ECHO model for enabling providers in rural communities to expand access to MAT as
well as its emphasis on provision of psychosocial services (Chou et al., 2016). While the
addition of Project ECHO to our model was recent, early results demonstrate increased
knowledge, decreased sense of professional isolation, and self-reported improvement in
ability to provide patient care that we hope will translate to increased capacity to treat
patients with OUD.
Significant strengths of our model for MAT for OUD are its scalability and adaptability.
With our OUD ECHO, we have trained 20 providers, but intend to reach up to 40 providers
per year in rural locations where access to buprenorphine remains limited. Through our Hub,
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we hope to provide further expertise to other community clinics through models such as the
Collaborative Opioid Prescribing Model (Stoller, 2015), with a goal to add an additional
three new spoke clinics per year for the next three years. Drawing on our relationships with
area hospitals, we will expand our offerings to include inpatient initiation of MAT
(Liebschutz et al., 2014). Finally, we recognize the need to expand access to evidence-based
MAT across the state and not merely in our region. Accordingly, we will engage policy
makers in Pennsylvania to encourage state Medicaid and commercial payors to reimburse
inpatient rehabilitation facilities that initiate MAT for OUD using buprenorphine or
methadone, rather than detoxification which does not address ongoing symptoms of
addiction.

5.

Conclusions

Author Manuscript

Primary care providers are on the front lines of the overdose epidemic, but, sadly, the
demand for treatment far exceeds the capacity to treat. Although MAT is the most effective
approach for the treatment of OUD, there are many barriers to incorporating MAT into
routine practice. Penn State’s Hub and Spoke MAT system of care is a unique answer to the
crisis as it is the only program in Pennsylvania that offers peer recovery specialists, access to
an entirely buprenorphine-waivered Emergency Department, and Project ECHO support for
providers. Our system is built on collaborative models of treatment that have proven
themselves effective both at reducing provider barriers to prescribing MAT and patient
barriers to engaging in treatment. We are hopeful that in time our model will establish a
standard of care for effective provision of MAT for OUD.
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Fig. 1.

Central PA MAT system of care.
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Fig. 2.

Hub and Spoke geographic catchment area
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Fig. 3.

Hub-and-Spoke Project ECHO model.
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Table 1

Author Manuscript

Example of 8 spoke clinic potential visit wait times prior to Hub-and-Spoke initiation.
Clinic site

Number of full-day clinics per month

Range of potential wait until next available appointment

Site 1

4

1–21 days

Site 2

20

1–3 days

Site 3

20

1–3 days

Site 4

8

1–5 days

Site 5

4

1–14 days

Site 6

4

1–7 days

Site 7

2

7–21 days

Site 8

8

1–5 days

Author Manuscript
Author Manuscript
Author Manuscript
J Subst Abuse Treat. Author manuscript; available in PMC 2020 May 01.

Kawasaki et al.

Page 17

Table 2

Author Manuscript

Demographics of patients seen within the first six months (November 2017–May 2018).
Demographics
Age (M; SD)

36.3 (11.33)

Gender
Male

112

62%

Female

67

37%

Transgender

1

1%

Caucasian

147

82%

African American

29

16%

Asian

3

2%

Non-Hispanic/Latino

165

92%

Hispanic/Latino

15

8%

a

Race

Ethnicity

Author Manuscript

a

One reported race as “unknown”.
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Table 3

Author Manuscript

Total number of patients seen per clinic type (November 2017–May 2018).

Author Manuscript

Spoke site type

Location

Total patients

Primary care FQHC-Clinic 1

Cumberland County

31

Primary care FQHC-Clinic 2

Cumberland County

39

Primary care FQHC-Clinic 1

Lancaster county

20

Primary care FQHC-Clinic 2

Lancaster county

20

Primary psychiatry

Lebanon County

42

Primary care-Clinic 1

Dauphin County

5

Primary care-Clinic 2

Dauphin County

37

Pain clinic

Franklin County

21

Emergency Department-1

Dauphin County

9

Emergency Department-2

Dauphin County

27

Probation/parole

Dauphin county

5

Opioid Intervention Court

Cumberland County

10
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